Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1963 2
1964 1
1965 1
1966 2
1968 1
1969 2
1971 5
1972 2
1973 2
1974 1
1975 1
1976 6
1977 3
1978 4
1979 6
1980 8
1981 9
1982 10
1983 14
1984 20
1985 15
1986 13
1987 5
1988 12
1989 25
1990 17
1991 13
1992 20
1993 19
1994 16
1995 12
1996 9
1997 9
1998 7
1999 13
2000 13
2001 10
2002 10
2003 8
2004 8
2005 4
2006 16
2007 9
2008 16
2009 14
2010 17
2011 28
2012 26
2013 31
2014 29
2015 22
2016 15
2017 30
2018 20
2019 27
2020 39
2021 32
2022 3
Text availability
Article attribute
Article type
Publication date

Search Results

674 results
Results by year
Filters applied: . Clear all
Page 1
Targeted Therapy and Immunotherapy for Melanoma in Japan.
Namikawa K, Yamazaki N. Namikawa K, et al. Among authors: yamazaki n. Curr Treat Options Oncol. 2019 Jan 24;20(1):7. doi: 10.1007/s11864-019-0607-8. Curr Treat Options Oncol. 2019. PMID: 30675668 Free PMC article. Review.
The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies.
Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. Kumagai S, et al. Among authors: yamazaki n. Nat Immunol. 2020 Nov;21(11):1346-1358. doi: 10.1038/s41590-020-0769-3. Epub 2020 Aug 31. Nat Immunol. 2020. PMID: 32868929
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, Grob JJ, Butler MO, Middleton MR, Maio M, Atkinson V, Queirolo P, Gonzalez R, Kudchadkar RR, Smylie M, Meyer N, Mortier L, Atkins MB, Long GV, Bhatia S, Lebbé C, Rutkowski P, Yokota K, Yamazaki N, Kim TM, de Pril V, Sabater J, Qureshi A, Larkin J, Ascierto PA; CheckMate 238 Collaborators. Weber J, et al. Among authors: yamazaki n. N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10. N Engl J Med. 2017. PMID: 28891423 Free article. Clinical Trial.
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion-Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Dummer R, et al. Among authors: yamazaki n. Lancet Oncol. 2018 May;19(5):603-615. doi: 10.1016/S1470-2045(18)30142-6. Epub 2018 Mar 21. Lancet Oncol. 2018. PMID: 29573941 Clinical Trial.
Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i.
Dummer R, Lebbé C, Atkinson V, Mandalà M, Nathan PD, Arance A, Richtig E, Yamazaki N, Robert C, Schadendorf D, Tawbi HA, Ascierto PA, Ribas A, Flaherty KT, Pakhle N, Campbell CD, Gusenleitner D, Masood A, Brase JC, Gasal E, Long GV. Dummer R, et al. Among authors: yamazaki n. Nat Med. 2020 Oct;26(10):1557-1563. doi: 10.1038/s41591-020-1082-2. Epub 2020 Oct 5. Nat Med. 2020. PMID: 33020648 Clinical Trial.
Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management.
Gogas HJ, Flaherty KT, Dummer R, Ascierto PA, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Sileni VC, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Gollerkeri A, Pickard MD, Robert C. Gogas HJ, et al. Among authors: yamazaki n. Eur J Cancer. 2019 Sep;119:97-106. doi: 10.1016/j.ejca.2019.07.016. Epub 2019 Aug 19. Eur J Cancer. 2019. PMID: 31437754 Free article. Clinical Trial.
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial.
Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, Chiarion Sileni V, Dutriaux C, de Groot JWB, Yamazaki N, Loquai C, Moutouh-de Parseval LA, Pickard MD, Sandor V, Robert C, Flaherty KT. Dummer R, et al. Among authors: yamazaki n. Lancet Oncol. 2018 Oct;19(10):1315-1327. doi: 10.1016/S1470-2045(18)30497-2. Epub 2018 Sep 12. Lancet Oncol. 2018. PMID: 30219628 Clinical Trial.
[Chromium].
Wada O, Yamazaki N. Wada O, et al. Among authors: yamazaki n. Nihon Rinsho. 1995 Feb;53 Su Pt 1:830-5. Nihon Rinsho. 1995. PMID: 8753565 Review. Japanese. No abstract available.
[Squamous cell carcinoma].
Yamazaki N. Yamazaki N. Gan To Kagaku Ryoho. 2006 Oct;33(10):1392-7. Gan To Kagaku Ryoho. 2006. PMID: 17033226 Review. Japanese.
Primary Cutaneous Rosai-Dorfman Disease of the Scalp.
Mizuta H, Nakano E, Yamazaki N. Mizuta H, et al. Among authors: yamazaki n. Dermatol Pract Concept. 2020 Dec 7;11(1):e2020086. doi: 10.5826/dpc.1101a86. eCollection 2021 Jan. Dermatol Pract Concept. 2020. PMID: 33354400 Free PMC article. No abstract available.
674 results